Arvanitis CD et al. |
Mechanisms of enhanced drug delivery in brain metastases with focused ultrasound-induced blood-tumor barrier disruption. |
2018 |
Proc. Natl. Acad. Sci. U.S.A. |
pmid:30150398
|
Moore KN et al. |
Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer. |
2018 |
Gynecol. Oncol. |
pmid:30093227
|
Wang L et al. |
STAT3 activation confers trastuzumab-emtansine (T-DM1) resistance in HER2-positive breast cancer. |
2018 |
Cancer Sci. |
pmid:30076657
|
Jin W et al. |
LC-HRMS quantitation of intact antibody drug conjugate trastuzumab emtansine from rat plasma. |
2018 |
Bioanalysis |
pmid:29863890
|
Menchon G et al. |
A fluorescence anisotropy assay to discover and characterize ligands targeting the maytansine site of tubulin. |
2018 |
Nat Commun |
pmid:29844393
|
Johnson TA and Singla DK |
Breast cancer drug trastuzumab induces cardiac toxicity: evaluation of human epidermal growth factor receptor 2 as a potential diagnostic and prognostic marker. |
2018 |
Can. J. Physiol. Pharmacol. |
pmid:29842793
|
Barok M et al. |
Cancer-derived exosomes from HER2-positive cancer cells carry trastuzumab-emtansine into cancer cells leading to growth inhibition and caspase activation. |
2018 |
BMC Cancer |
pmid:29720111
|
Sakai H et al. |
HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer. |
2018 |
Breast Cancer |
pmid:29700710
|
Escrivá-de-Romanà S et al. |
HER2-positive breast cancer: Current and new therapeutic strategies. |
2018 |
Breast |
pmid:29631097
|
Moore KN et al. |
FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer. |
2018 |
Future Oncol |
pmid:29424243
|
Ricciardi GRR et al. |
Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: new directions for systemic therapy - a case report and literature review. |
2018 |
BMC Cancer |
pmid:29370839
|
Yeo W et al. |
Efficacy and tolerability of trastuzumab emtansine in advanced human epidermal growth factor receptor 2-positive breast cancer. |
2018 |
Hong Kong Med J |
pmid:29326401
|
Gligorov J et al. |
Emilia: use cunning to survive cancer. |
2018 |
Chin Clin Oncol |
pmid:29307196
|
Mohamed HE et al. |
Stability assessment of antibody-drug conjugate Trastuzumab emtansine in comparison to parent monoclonal antibody using orthogonal testing protocol. |
2018 |
J Pharm Biomed Anal |
pmid:29258046
|
Doroshow DB and LoRusso PM |
Trastuzumab emtansine: determining its role in management of HER2+ breast cancer. |
2018 |
Future Oncol |
pmid:29214842
|
Hurvitz SA et al. |
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. |
2018 |
Lancet Oncol. |
pmid:29175149
|
Ricci F and Le Tourneau C |
Trastuzumab emtansine in HER2-positive metastatic breast cancer: what is the best sequence? |
2018 |
Chin Clin Oncol |
pmid:29156892
|
Moore KN et al. |
A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer. |
2018 |
Future Oncol |
pmid:29098867
|
Zuradelli M et al. |
Never too old to fight breast cancer: A case report. |
2018 |
Medicine (Baltimore) |
pmid:29489698
|
Madden R et al. |
Lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer: A systematic review
. |
2018 |
Int J Clin Pharmacol Ther |
pmid:29231164
|
Vilela MD et al. |
Progressively Enlarging Cerebellar Hematoma Concurrent with T-DM1 Treatment. |
2018 |
World Neurosurg |
pmid:29274446
|
Nittoli T et al. |
Antibody drug conjugates of cleavable amino-alkyl and aryl maytansinoids. |
2018 |
Bioorg. Med. Chem. |
pmid:29605304
|
Schwarz LJ et al. |
An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression. |
2017 |
J. Natl. Cancer Inst. |
pmid:29059433
|
Chen SC et al. |
Population pharmacokinetics of trastuzumab emtansine in previously treated patients with HER2-positive advanced gastric cancer (AGC). |
2017 |
Cancer Chemother. Pharmacol. |
pmid:29043411
|
La Monica S et al. |
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines. |
2017 |
J. Exp. Clin. Cancer Res. |
pmid:29202823
|
Fabi A et al. |
Ado-trastuzumab emtansine (T-DM1) in HER2+ advanced breast cancer patients: does pretreatment with pertuzumab matter? |
2017 |
Future Oncol |
pmid:29182361
|
Zhang J et al. |
Safety and efficacy of the addition of pertuzumab to T-DM1 ± taxane in patients with HER2-positive, locally advanced or metastatic breast cancer: a pooled analysis. |
2017 |
Drug Des Devel Ther |
pmid:29180848
|
Thuss-Patience PC et al. |
Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. |
2017 |
Lancet Oncol. |
pmid:28343975
|
Beck A et al. |
Strategies and challenges for the next generation of antibody-drug conjugates. |
2017 |
Nat Rev Drug Discov |
pmid:28303026
|
Chuang JC et al. |
ERBB2-Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies. |
2017 |
J Thorac Oncol |
pmid:28167203
|
Liu Y et al. |
LC-MS/MS method for the simultaneous determination of Lys-MCC-DM1, MCC-DM1 and DM1 as potential intracellular catabolites of the antibody-drug conjugate trastuzumab emtansine (T-DM1). |
2017 |
J Pharm Biomed Anal |
pmid:28131055
|
Daniels B et al. |
Use and outcomes of targeted therapies in early and metastatic HER2-positive breast cancer in Australia: protocol detailing observations in a whole of population cohort. |
2017 |
BMJ Open |
pmid:28119394
|
Kosmin M et al. |
Splenic Enlargement and Bone Marrow Hyperplasia in Patients Receiving Trastuzumab-Emtansine for Metastatic Breast Cancer. |
2017 |
Target Oncol |
pmid:28110417
|
Andreev J et al. |
Bispecific Antibodies and Antibody-Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs. |
2017 |
Mol. Cancer Ther. |
pmid:28108597
|
Schönfeld K et al. |
Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies. |
2017 |
J Hematol Oncol |
pmid:28077160
|
Moore KN et al. |
Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study. |
2017 |
J. Clin. Oncol. |
pmid:28029313
|
Geraud A et al. |
Preliminary experience of the concurrent use of radiosurgery and T-DM1 for brain metastases in HER2-positive metastatic breast cancer. |
2017 |
J. Neurooncol. |
pmid:27995546
|
Yap LW et al. |
Role of CD56 in Normal Kidney Development and Wilms Tumorigenesis. |
2017 |
Fetal Pediatr Pathol |
pmid:27935326
|
Wang LL et al. |
A Bio-Chemosynthetic Approach to Superparamagnetic Iron Oxide-Ansamitocin Conjugates for Use in Magnetic Drug Targeting. |
2017 |
Chemistry |
pmid:27935144
|
Mercogliano MF et al. |
TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer. |
2017 |
Clin. Cancer Res. |
pmid:27698002
|
Baldassarre T et al. |
Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers. |
2017 |
Breast Cancer Res. |
pmid:28974266
|
Ning X et al. |
Identification and Engineering of Post-PKS Modification Bottlenecks for Ansamitocin P-3 Titer Improvement in Actinosynnema pretiosum subsp. pretiosum ATCC 31280. |
2017 |
Biotechnol J |
pmid:28881098
|
van Boxtel W et al. |
Combination of docetaxel, trastuzumab and pertuzumab or treatment with trastuzumab-emtansine for metastatic salivary duct carcinoma. |
2017 |
Oral Oncol. |
pmid:28673692
|
Martin LP et al. |
Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine. |
2017 |
Gynecol. Oncol. |
pmid:28843653
|
Wang H et al. |
Aberrant intracellular metabolism of T-DM1 confers T-DM1 resistance in human epidermal growth factor receptor 2-positive gastric cancer cells. |
2017 |
Cancer Sci. |
pmid:28388007
|
Lambert JM and Morris CQ |
Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review. |
2017 |
Adv Ther |
pmid:28361465
|
Socinski MA et al. |
Phase 1/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small-Cell Lung Cancer Patients With Extensive-Stage Disease. |
2017 |
Clin Lung Cancer |
pmid:28341109
|
Carvajal-Hausdorf DE et al. |
Objective, domain-specific HER2 measurement in uterine and ovarian serous carcinomas and its clinical significance. |
2017 |
Gynecol. Oncol. |
pmid:28196634
|
Perez EA et al. |
Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study. |
2017 |
J. Clin. Oncol. |
pmid:28056202
|
Parikh A et al. |
Prolonged Response to HER2-Directed Therapy in a Patient With HER2-Amplified, Rapidly Progressive Metastatic Colorectal Cancer. |
2017 |
J Natl Compr Canc Netw |
pmid:28040715
|